Form 4: BioMarin Executive George Eric Davis Reports Stock Transactions
SEC Form 4 Filing
EVP, Chief Legal Officer of BioMarin Pharmaceutical Inc., George Eric Davis, reports acquisition of stock options and restricted stock units, as well as disposition of shares to cover tax obligations.
Summary
- On March 15, 2024, George Eric Davis, EVP, Chief Legal Officer of BioMarin Pharmaceutical Inc., reported transactions involving the company's stock.
- Davis acquired 10,260 shares of common stock at $0, representing restricted stock units granted.
- He also disposed of 21,699 shares of common stock at a price of $83.87.
- Following these transactions, Davis beneficially owns 80,458 shares of common stock.
- Davis also acquired 22,990 stock options with an exercise price of $83.87, exercisable starting March 15, 2025, and expiring on March 14, 2034.
- Following these transactions, Davis beneficially owns 22,990 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing is a routine disclosure of stock transactions. The acquisition of stock options and restricted stock units is a positive sign, while the disposal of shares is likely for tax purposes and doesn't necessarily indicate a negative outlook.
Positives
- The acquisition of restricted stock units and stock options suggests confidence in the company's future performance.
Negatives
- The disposal of shares, although likely for tax obligations, could be perceived negatively by some investors if not understood in context.
Risks
- There are no specific risks mentioned in this document, but standard risks associated with stock ownership and option grants apply.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule of the stock options suggests a long-term incentive for the executive.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company executives and their confidence in the company's prospects.
Comparison to Industry Standards
- Stock option grants and restricted stock units are common forms of executive compensation in the pharmaceutical industry.
- Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize these instruments to align executive interests with shareholder value.
- The vesting schedules and exercise prices are typically benchmarked against industry standards to attract and retain talent.
Stakeholder Impact
- Shareholders may be interested in the transactions of company executives as an indicator of management's confidence in the company.
- Employees may view the stock option grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of the reported transactions: acquisition of stock options and restricted stock units, and disposition of shares. |
| 03/15/2025 | First date that the acquired stock options become exercisable (12/48th of the options). |
| 03/14/2034 | Expiration date of the acquired stock options. |
| 03/19/2024 | Date of the signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.